Loren Data's SAM Daily™

FBO DAILY ISSUE OF AUGUST 28, 2002 FBO #0269
SOLICITATION NOTICE

A -- Pilot Study of Medication Use and Risk of Esophageal Adenocarcinoma and Barrett''s Esophagus

Notice Date

8/26/2002
 

Notice Type

Solicitation Notice
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
 

ZIP Code

20852
 

Solicitation Number

NCI-20122-NG
 

Response Due

9/3/2002
 

Point of Contact

Malinda Holdcraft, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Caren Rasmussen, Lead Contract Specialist, Phone (301) 402-4509, Fax (301) 402-4513,
 

E-Mail Address

holdcram@exchange.nih.gov, cr214i@nih.gov
 

Description

The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Occupational Epidemiology Branch (OEB) plans to procure services with Henry Ford Hospital, Science Center, 2799W Grand Boulevard, Detroit, Michigan 48202 for a Pilot Study of Medication Use and Risk of Esophageal Adenocarcinoma and Barrett's Esophagus. The acquisition is being made in accordance with the test program for using simplified procedures for certain commercial items as authorized in FAR Part 13. The North American Industry Classification System code is 541990 and the business size standard is $6M. The Occupational Epidemiology Branch plans to examine the association between medications that relax the lower esophageal sphincter (LES) and the risk of esophageal adenocarcinoma and Barrett's esophagus. The analyses must address the following public health questions: 1) the risk of esophageal adenocarcinoma and Barrett's esophagus related to the use of specific medications, 2) the risk associated with the use of combinations of such medications, 3) the dose-response relations in terms of both duration of use and prescribed dose, and 4) the associations between esophageal adenocarcinoma and certain medical conditions potentially on the causal pathway, such as Barrett's esophagus and gastroesophageal reflux disease (GERD). Two previous studies have examined the relationship between medication use and esophageal adenocarcinoma have relied on self-reported medication use information, which is subject to both differential and nondifferential misclassification. To overcome the limitations associated with self-reported data, these new analyses must use accurate, objective, and detailed medication use data (including prescribed dose, frequency of prescription refills, and duration of use) in conjunction with detailed information on the cancer and other medical conditions of interest. Minimum Requirements: 1) Contractor shall have access to a large study population of at least 250,000 men and women with prepaid health care, with detailed prospective data on prescription medication use, selected medical conditions, and cancer outcomes. This data must be available for epidemiologic analysis; 2) have sufficient power to assess the relationship between individual medication use and risk of esophageal adenocarcinoma; 3) the study needs to have detailed long-term computerized data on medication use, and that data must be linked to patients diagnosed with esophageal adenocarcinoma and other medical conditions being examined; 4) the study population shall include at least 12% of African Americans. Period of Performance: upon award of purchase order through 12 months. FAR Clause 52.217-8 Option to Extend Services (November 1999) and FAR Clause 52.217-9 Option to Extend the Term of the Contract (March 2000) applies to this order. Henry Ford Hospital is the only known source to the NCI that can provide the aforementioned minimum requirements. This is not a request for competitive quotations. However, if any interested party believes it can perform the above requirement, it may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient detail to allow NCI to determine if it can meet the above minimum specifications described herein. Capability statements must be received in the Contracting Office by 1:00 PM EDT (local Washington D.C. time) on September 3, 2002. If you have and questions, please contact Malinda Holdcraft, Purchasing Agent via electronic mail at holdcram@excange.nih.gov or by fax at (301) 402-4513. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received shall be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted.
 

Place of Performance

Address: NIH/NCI, 9000 Rockville Pike, Bethesda, MD

Zip Code: 20892

Country: USA
 

Record

SN00149877-W 20020828/020826213225 (fbodaily.com)
 

Source

FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |